-
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
-
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
-
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
-
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada
-
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
-
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
-
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause